Market Overview

Biotech Stocks Sell Off, ETFs Fall Over 5%

Related IBB
What Pharmaceuticals Spend On Lobbying To Influence Trump
This Drug, An Alternative To Marijuana And Ketamine, Could Treat Suicidal Depression And PTSD
Related FBT
Once Beloved Momentum ETF Loses Its Momo
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech

Biotech stocks declined Tuesday as the broader market climbed to new highs. Biotech ETFs that fell more than 5 percent included:

  • iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB)
  • First Trust NYSE Arca Biotechnology Index Fund (EFT) (NYSE: FBT)
  • SPDR S&P Biotech (ETF) (NYSE: XBI)

Investors may see opportunities to buy individual stocks on weakness. Below are the top five holdings of each fund.

iShares NASDAQ Biotechnology Index:
Celgene Corporation (NASDAQ: CELG)
Amgen, Inc. (NASDAQ: AMGN)
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
Gilead Sciences, Inc. (NASDAQ: GILD)
Biogen Idec Inc (NASDAQ: BIIB)

First Trust NYSE Arca Biotechnology Index Fund:
Incyte Corporation (NASDAQ: INCY)
Nektar Therapeutics (NASDAQ: NKTR)
ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS)
Celgene Corporation (NASDAQ: CELG)
Alkermes Plc (NASDAQ: ALKS)

SPDR S&P Biotech:
Agios Pharmaceuticals Inc (NASDAQ: AGIO)
Receptos Inc (NASDAQ: RCPT)
Incyte Corporation (NASDAQ: INCY)
Geron Corporation (NASDAQ: GERN)
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)

Among the biggest losers Tuesday were ISIS Pharmaceuticals, which recently traded at $57.16 (down 9.1 percent) and Agios Pharmaceuticals, which recently traded at $108.32 (down 10.07 percent).

Posted-In: Long Ideas News Short Ideas Intraday Update Trading Ideas ETFs


Related Articles (FBT + AGIO)

View Comments and Join the Discussion!